1[1]NowakMA,BonhoefferS.Hill AM,et al.Viral dynamics in hepatitis B virus infection[J].Proc Natl Acad Sci USA,1996,93:4 398-402.
2[2]Richman DD.The impact of drug resistane on the effectiveness of chemotherapy for chronic hepatitis B[J].Hepatology,2000,32:866-867.
3[3]Locarnini S,HatzaKis A,Heathcote J,et al.Management of aneiviraal resistancein patients with chronic hepatitis B[J].Antivir Ther,2004,9:679-93.
4[4]ZoulimF.Virology of hepatitis B[M].ELSEVIER,2004:43.
5[5]Colonne R,Rose R,Levine S,et al.Entecavir two year resistance update:no resistance obserevd in nucledide naive patients and low frequency resistance emergence in lamivudine.refractory patients[J].Hepatology,2005,42(s):962.
7[7]Leung N W,Lai CL,ChangTT,et al.Extended lamivudine treatment in patients with chronic hepatitis B enhanceshepatitis B e antigen seroconversion rates:results after 3 years of therapy[J].Hepatology,2001.33:1527-1532.
8[8]Bock CT,Tillman H,Torresi J,et al.Selection of hepatitis B virus polymerase mutants with enhanced replication by Lamivudine treatment after liver transplantion[J].GastroEnterology,2002,122(2):264-273.
9[9]One Sk,Kato N,Shiratoriy,et al.The polymerase L528M mutation cooperates with mucleotide bingdiug-site mutatiobs increasing hepatitis B virus replication and drug resistante[J].T J clin Invest,2001,107(4):449-455.
10[10]Bartholomeusz A,Locarmini S,Ayves A,et al.Molecular modelling of hepatitis B virus polymerase and Adefovir resistance identifies three clusters ofmutations[J].Hepatology,2004,40:246A.
二级参考文献60
1[1]Hepatitis B Foundation.What is hepatitis B? Statistics,2005:18.
3[3]Moyer LA,Mast EE.Hepatitis B:virology,epidemiology,disease,and prevention and an overview of viral hepatitis.Am J Prey Med,1994,10 (suppl):45-55.
4[4]World Health Organization Department of Communicable Disease Surveillance and Response.Hepatitis B-an introduction.Available at:www.who.int/ emc-documents/ hepatitis/ docs/ whocdscsrlyo20022/ introduction/ introduction.html.Last update:January,2005.Accessed May 5,2005.
5[5]Cihlar T,Lin DC,Pritchard JB,Fuller MD,Mendel DB,Sweet DH.The antivirul nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.Mol Pharmacol,1999,56:570-580.
6[6]Lok AS.New treatment of chronic hepatitis B.Semin Liver Dis,2004,24(suppl 1):77-82.
7[7]Marcellin P.Adefovir dipivoxil for the treatment of hepatitis B e antigenposititive chronic hepatitis B.N Engl J Med,2003,348:808-816.
8[8]Santantonio T,Mazzola M,Iacovazzi T,Miglietta A,Guastadisegni A,Pastore G.Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.J Hepatol,2000,32:300-306.
9[9]Tassopoulos NC,Volpes R,Pastore G,et al.Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group.Hepatology,1999,29:889-896.
10[10]Food and Drug Administration Center of Drug Evaluation.And Research.Approval Letter:BaracludeTM Available at:www.fda.gov/cder/foi/appletter/2005/021797,021798ltr,pdf.Last update:2005.Accessed 2005.
3Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
